Partial
Partially Aligned
Patient Risk:
Medium
Summary
Only the all-cause mortality warning content appears supported by the provided FDA labeling. Several other claims about hepatotoxicity and liver monitoring are not evaluated/supported by the supplied labeling excerpts, and some monitoring frequency assertions reference external guidance not present in the label.
Category Scores
Accurate Statements
An increase in all-cause mortality has been observed in TYGACIL-treated patients versus comparator.
BOX All-Cause Mortality and Section 5.1 both state an increase in all-cause mortality vs comparator.
The adjusted risk difference of all-cause mortality is 0.6% (95% CI 0.1, 1.2) and the cause has not been established.
BOX All-Cause Mortality and Section 5.1 both include the 0.6% (95% CI 0.1, 1.2) estimate and that the cause has not been established.
TYGACIL should be reserved for use when alternative treatments are not suitable.
BOX All-Cause Mortality and Section 5.1 both include the reserve-for-alternatives instruction.
Unsupported Statements
Tigecycline is used to treat serious infections, including pneumonia, sepsis, and intra-abdominal infections.
No FDA label indication text was provided in the prompt for validation of these specific disease targets.
Tigecycline has been associated with hepatotoxicity, including increased liver enzymes and liver failure.
The provided FDA excerpts only mention 'Hepatic Adverse Effects [see Warnings and Precautions (5.4)]' without stating hepatotoxicity manifestations or liver failure.
The incidence of liver damage in patients treated with tigecycline was reported as 1.4%.
No FDA label text provided in the prompt supplies the 1.4% incidence.
The FDA recommends monitoring liver function in patients treated with tigecycline.
The provided FDA excerpts do not include a liver-function monitoring recommendation by FDA.
The frequency and duration of FDA liver-function monitoring for tigecycline are not specified.
Since FDA monitoring instructions are not shown in the provided label excerpts, the claim cannot be confirmed from the supplied text.
The IDSA recommends monitoring LFTs at baseline and 3-5 days after initiation of tigecycline therapy.
IDSA guidance is not part of the supplied FDA labeling excerpts.
The IDSA recommends monitoring LFTs every 3-5 days during tigecycline therapy.
IDSA guidance is not part of the supplied FDA labeling excerpts.
The IDSA recommends monitoring LFTs as clinically indicated during tigecycline therapy.
IDSA guidance is not part of the supplied FDA labeling excerpts.
Patients with pre-existing liver disease should be closely monitored while taking tigecycline.
No FDA label excerpt provided states monitoring for patients with pre-existing liver disease.
The frequency and duration of liver-function monitoring while taking tigecycline are not specified.
No FDA liver-monitoring frequency/duration language was provided in the prompt.
Contradictions
Important Omissions
All-cause mortality counseling in the response is not shown as an evaluated/quoted claim set; only the mortality label section is evaluable from the provided excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
Some label-supported safety claims (all-cause mortality reserve language) appear accurate, but multiple liver-related claims (including liver failure, incidence, and monitoring recommendations) are not supported by the supplied FDA label excerpts. This could lead to inaccurate safety/monitoring expectations if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Non-label-supported liver-monitoring and hepatotoxicity/liver-failure details are included without corresponding FDA label excerpts.
Suggested Improvement
Limit safety discussion to the supplied FDA label content for the all-cause mortality boxed warning (Sections Box and 5.1) and any other label excerpts provided for hepatic adverse effects and monitoring; remove or rephrase claims (e.g., 1.4% incidence, FDA recommendation, IDSA monitoring schedule, liver failure) unless supported directly by the provided FDA prescribing information.